Valneva (NASDAQ:VALN) Upgraded by TD Cowen to “Strong-Buy” Rating

TD Cowen upgraded shares of Valneva (NASDAQ:VALN) to a strong-buy rating in a research note released on Tuesday morning,Zacks.com reports.

A number of other research firms also recently issued reports on VALN. The Goldman Sachs Group downgraded Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Guggenheim set a $11.00 target price on shares of Valneva in a research report on Thursday, April 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.98.

Valneva Stock Performance

NASDAQ:VALN opened at $5.59 on Tuesday. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. The firm’s fifty day simple moving average is $5.21 and its 200 day simple moving average is $6.98. The stock has a market cap of $530.44 million, a P/E ratio of -2.99 and a beta of 1.77. Valneva has a twelve month low of $4.75 and a twelve month high of $12.25.

Valneva (NASDAQ:VALN) last posted its earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.The company had revenue of $35.77 million during the quarter. As a group, research analysts predict that Valneva will post -1 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in shares of Valneva during the 4th quarter valued at approximately $94,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva in the fourth quarter worth $44,000. JPMorgan Chase & Co. bought a new stake in shares of Valneva during the 3rd quarter valued at $124,000. Finally, Marex Group plc bought a new stake in shares of Valneva during the 2nd quarter valued at $64,000. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.